Table 4.
Prognostic performance of ProMisE and TransPORTEC classifiers, adapted from (49) and (48), respectively.
| Subgroups | N (%) | Overall survival | Disease specific survival | Progression free survival | |||
|---|---|---|---|---|---|---|---|
| ProMisE | HR(95%CI) | LRT p | HR(95%CI) | LRT p | HR(95%CI) | LRT p | |
| p53 wt | 139 (45.6%) | Comparator group | |||||
| MMR-D | 64 (20.1%) | 1.90 (0.88-4.04) | 0.0211 | 1.32 (0.51-3.35) | 0.0156 | 0.64 (0.25-1.60) | 0.011 |
| POLE EDM | 30 (9.4%) | 1.01(0.26-2.99) | 0.42 (0.04-1.88) | 0.19 (0.02-0.81) | |||
| P53 abn | 86 (27.0%) | 2.61 (1.27-5.72) | 2.28 (1.02-5.58) | 1.75 (0.84-3.96) | |||
| TransPORTEC | 5-year overall survival | Distant recurrence rates | 5-year recurrence free survival | ||||
| NSMP | 44 (38%) | 61% | <0.001 | 39% | <0.001 | 52% | <0.001 |
| MSI-high | 19 (16%) | 63% | 0% | 95% | |||
| POLE mutant | 14 (12%) | 93% | 0% | 93% | |||
| p53 abnormal | 39 (34%) | 40% | 50% | 42% | |||
ProMisE data are based on multivariable analysis in a validation cohort of 319 cancers. Variables included in model are age, BMI, grade, histology, any treatment received. TransPORTEC data included 116 high risk endometrial cancer patients. HR, hazard ratio; LRP, likelihood ratio test.